ArticlePloS one2025
Estimating the clinical and economic burden of medically attended influenza in South Korea, stratified by age and comorbidity: A five-season hospital-based surveillance data, 2014/15-2018/19.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Influenza Vaccine Effectiveness in Korea: A Systematic Review and Meta-Analysis of Real-World Evidence from the Past Decade.Vaccines · 2026Review
- Influenza virus research in an era of emerging respiratory threats: host-virus interactions, surveillance technologies, antiviral management and resistance, and vaccine preparedness.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to estimate the clinical and economic burden of influenza in South Korea across five seasons (2014/15-2018/19), stratified by age and comorbidity, using data from the Hospital-based Influenza Morbidity and Mortality (HIMM) network.
methodsData were gathered from eight university hospitals and included adults (≥ 20 years) with laboratory-confirmed influenza. The catchment population was estimated using hospital and national statistical data. Economic costs were evaluated from a societal perspective.
resultsThe incidence of medically attended influenza ranged from 113.1 to 220.7 per 100,000 adults, with hospitalization rate of 35.5 to 76.8, intensive care unit admission at 4.2 to 9.2, and deaths at 1.4 to 3.6. Annual socioeconomic costs ranged from $156 to $316 million, primarily driven by indirect costs associated with early mortality. The highest cost was recorded in 2017/18, following the largest outbreak, particularly among older adults. Per capita socioeconomic costs ranged from $2,747 to $4,072 across the seasons, with peak values observed in 2018/19 and 2015/16. Among at-risk groups, per capita costs were 1.5-2.3 times higher than those of the general adult population.
conclusionsInfluenza imposes a significant clinical and economic burden on South Korea. Tailored strategies are essential to mitigate this burden, particularly among older adults and at-risk individuals not covered by the National Immunization Program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.